Skip to content

Author

C.-S. Huang

We have 2 of 431 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.

Positive OS results with a clinically relevant benefit of ribociclib plus NSAI are demonstrated, consistent with the increasing reduction in recurrence risk, and reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.

D. Slamon, G. Hortobagyi, D. Stroyakovskiy et al. · 1 citation
Open access Oct 2026

Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.

BACKGROUND Atirmociclib is a potential first-in-class, highly selective cyclin-dependent kinase (CDK) 4 inhibitor, demonstrating significantly greater selectivity over CDK6. In a phase 1/2a study, atirmociclib plus endocrine therapy was well tolerated and showed encouraging antitumor activity in patients with HR+/HER2-...

A. Giordano, B. Xu, T. Yoshinami et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.